METASTATIC NEUROENDOCRINE TUMOR
Clinical trials for METASTATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for METASTATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost radiation therapy for neuroendocrine tumors
Disease control OngoingThis phase II trial tests whether adding the drug triapine to standard radioactive therapy (lutetium Lu 177 dotatate) helps shrink or slow the growth of metastatic neuroendocrine tumors. About 94 adults with well-differentiated, somatostatin receptor-positive tumors will be rando…
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug shows promise in slowing rare carcinoid tumors
Disease control OngoingThis study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets Hard-to-Treat gut tumors
Disease control OngoingThis early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC